PE20240657A1 - Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicos - Google Patents
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicosInfo
- Publication number
- PE20240657A1 PE20240657A1 PE2023003180A PE2023003180A PE20240657A1 PE 20240657 A1 PE20240657 A1 PE 20240657A1 PE 2023003180 A PE2023003180 A PE 2023003180A PE 2023003180 A PE2023003180 A PE 2023003180A PE 20240657 A1 PE20240657 A1 PE 20240657A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- oxoisoindolin
- dione
- piperidine
- hemoglobinopathies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a compuestos derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona de formula I', o una de sus sales, hidratos, solvatos, profarmacos, estereoisomeros o tautomeros farmaceuticamente aceptables, donde: cada R1 se selecciona de manera independiente de H, C1-C6alquilo, hidroxilo, entre otros; R2 se selecciona de H, C3-C11cicloalquilo, heterociclilo de 4 a 11 miembros que comprende 1-2 heteroatomos seleccionados de manera independiente de N, O, y S, C1-C6haloalquilo, entre otros; n es 0, 1, 2, 3, 4 o 5; y m es 0, 1 o 2. Estos compuestos reducen los niveles de expresion de proteinas que contiene de dedos de zinc ampliamente interespaciados (WIZ), o para inducir la expresion de la hemoglobina fetal (HbF). Tambien se refiere a la preparacion de dichos compuestos, sus compuestos intermedios, una composicion farmaceutica que comprende dichos compuestos y su uso en el tratamiento de trastornos sanguineos hereditarios, como hemoglobinopatias, beta-hemoglobinopatias, enfermedad de celulas falciformes y beta-talasemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196422P | 2021-06-03 | 2021-06-03 | |
| PCT/IB2022/055131 WO2022254362A1 (en) | 2021-06-03 | 2022-06-01 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240657A1 true PE20240657A1 (es) | 2024-04-04 |
Family
ID=82115547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023003180A PE20240657A1 (es) | 2021-06-03 | 2022-06-01 | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12103919B2 (es) |
| EP (1) | EP4347580A1 (es) |
| JP (1) | JP2024520654A (es) |
| KR (1) | KR20240013812A (es) |
| CN (1) | CN117062811A (es) |
| AR (1) | AR126052A1 (es) |
| AU (1) | AU2022284366A1 (es) |
| BR (1) | BR112023024905A2 (es) |
| CA (1) | CA3215410A1 (es) |
| CL (1) | CL2023003561A1 (es) |
| CO (1) | CO2024000013A2 (es) |
| CR (1) | CR20230614A (es) |
| DO (1) | DOP2023000261A (es) |
| EC (1) | ECSP24000004A (es) |
| IL (1) | IL308094A (es) |
| MX (1) | MX2023014327A (es) |
| PE (1) | PE20240657A1 (es) |
| TW (1) | TW202306570A (es) |
| UY (1) | UY39796A (es) |
| WO (1) | WO2022254362A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| PE20242225A1 (es) | 2022-03-17 | 2024-11-19 | Gilead Sciences Inc | Degradadores de dedos de zinc de la familia ikaros y usos de estos |
| TW202434562A (zh) | 2022-11-04 | 2024-09-01 | 美商必治妥美雅史谷比公司 | 化合物及其用於治療血紅素病變之用途 |
| US20250333407A1 (en) * | 2024-04-29 | 2025-10-30 | Bristol-Myers Squibb Company | Compounds and Their Use for Treatment of Hemoglobinopathies |
| WO2026002044A1 (zh) * | 2024-06-25 | 2026-01-02 | 标新生物医药科技(上海)有限公司 | 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP4289838A3 (en) | 2010-02-11 | 2024-03-13 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| MX2013005434A (es) | 2010-11-18 | 2013-09-26 | Deuteria Pharmaceuticals Inc | 3´ - deutero - polidomida. |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| JP2015524811A (ja) | 2012-07-27 | 2015-08-27 | セルジーン コーポレイション | イソインドリン−１，３−ジオン化合物の調製プロセス |
| WO2017024019A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| CN109071552B (zh) | 2016-04-22 | 2022-06-03 | 达纳－法伯癌症研究所公司 | 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法 |
| ES2945224T3 (es) | 2016-10-11 | 2023-06-29 | Arvinas Operations Inc | Compuestos y métodos para la degradación dirigida del receptor de andrógenos |
| KR102570992B1 (ko) | 2016-11-01 | 2023-08-28 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| CN110291087B (zh) * | 2016-12-01 | 2024-07-09 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
| WO2018119441A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| US10723717B2 (en) | 2016-12-23 | 2020-07-28 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| US10604506B2 (en) | 2017-01-26 | 2020-03-31 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| WO2019079569A1 (en) | 2017-10-18 | 2019-04-25 | Novartis Ag | COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN |
| EP3676268A1 (en) | 2017-10-20 | 2020-07-08 | Dana-Farber Cancer Institute, Inc. | Heterobifunctional compounds with improved specificityfor the bromodomain of brd4 |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11028088B2 (en) | 2018-03-10 | 2021-06-08 | Yale University | Modulators of BTK proteolysis and methods of use |
| CN112218859B (zh) | 2018-04-04 | 2024-10-29 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| EP3814330A4 (en) | 2018-06-29 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
| WO2020006262A1 (en) | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | New crbn modulators |
| US12060366B2 (en) | 2018-06-29 | 2024-08-13 | Dana-Farber Cancer Institute, Inc. | Bispecific degraders |
| KR20210025061A (ko) | 2018-06-29 | 2021-03-08 | 다나-파버 캔서 인스티튜트 인크. | 세레블론(crbn)에 대한 리간드 |
| LT3820573T (lt) * | 2018-07-10 | 2023-11-10 | Novartis Ag | 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diono dariniai ir jų naudojimas gydyti nuo ikaros šeimos cinko pirštų 2 (ikzf2) priklausomas ligas |
| JP7709378B2 (ja) * | 2018-12-03 | 2025-07-16 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法 |
| EP4031243A1 (en) | 2019-09-16 | 2022-07-27 | Novartis AG | Glue degraders and methods of use thereof |
| JP2022552006A (ja) * | 2019-10-17 | 2022-12-14 | アルヴィナス・オペレーションズ・インコーポレイテッド | Ｂｃｌ６標的化部分に連結されたｅ３ユビキチンリガーゼ結合部分を含有する二官能性分子 |
| JOP20220152A1 (ar) * | 2019-12-18 | 2023-01-30 | Novartis Ag | مشتقات 3-(5- ميثوكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخداماتها |
-
2022
- 2022-06-01 AU AU2022284366A patent/AU2022284366A1/en not_active Abandoned
- 2022-06-01 WO PCT/IB2022/055131 patent/WO2022254362A1/en not_active Ceased
- 2022-06-01 CR CR20230614A patent/CR20230614A/es unknown
- 2022-06-01 KR KR1020237045016A patent/KR20240013812A/ko active Pending
- 2022-06-01 EP EP22731823.5A patent/EP4347580A1/en active Pending
- 2022-06-01 PE PE2023003180A patent/PE20240657A1/es unknown
- 2022-06-01 BR BR112023024905A patent/BR112023024905A2/pt not_active Application Discontinuation
- 2022-06-01 US US17/829,933 patent/US12103919B2/en active Active
- 2022-06-01 TW TW111120484A patent/TW202306570A/zh unknown
- 2022-06-01 UY UY0001039796A patent/UY39796A/es unknown
- 2022-06-01 JP JP2023574412A patent/JP2024520654A/ja active Pending
- 2022-06-01 AR ARP220101454A patent/AR126052A1/es not_active Application Discontinuation
- 2022-06-01 CN CN202280022964.9A patent/CN117062811A/zh active Pending
- 2022-06-01 CA CA3215410A patent/CA3215410A1/en active Pending
- 2022-06-01 IL IL308094A patent/IL308094A/en unknown
- 2022-06-01 MX MX2023014327A patent/MX2023014327A/es unknown
-
2023
- 2023-11-29 DO DO2023000261A patent/DOP2023000261A/es unknown
- 2023-11-29 CL CL2023003561A patent/CL2023003561A1/es unknown
-
2024
- 2024-01-02 CO CONC2024/0000013A patent/CO2024000013A2/es unknown
- 2024-01-02 EC ECSENADI20244A patent/ECSP24000004A/es unknown
- 2024-09-03 US US18/823,254 patent/US20250026736A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230614A (es) | 2024-02-01 |
| TW202306570A (zh) | 2023-02-16 |
| DOP2023000261A (es) | 2023-12-29 |
| CN117062811A (zh) | 2023-11-14 |
| US20230019617A1 (en) | 2023-01-19 |
| CA3215410A1 (en) | 2022-12-08 |
| US20250026736A1 (en) | 2025-01-23 |
| US12103919B2 (en) | 2024-10-01 |
| MX2023014327A (es) | 2023-12-13 |
| CO2024000013A2 (es) | 2024-01-25 |
| JP2024520654A (ja) | 2024-05-24 |
| EP4347580A1 (en) | 2024-04-10 |
| WO2022254362A1 (en) | 2022-12-08 |
| AR126052A1 (es) | 2023-09-06 |
| UY39796A (es) | 2023-07-31 |
| ECSP24000004A (es) | 2024-02-29 |
| AU2022284366A1 (en) | 2023-10-26 |
| BR112023024905A2 (pt) | 2024-02-20 |
| IL308094A (en) | 2023-12-01 |
| CL2023003561A1 (es) | 2024-06-28 |
| KR20240013812A (ko) | 2024-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240657A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicos | |
| CO2022008243A2 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos | |
| GT199900008A (es) | Compuestos 4-(2-ceto-1-benzilimidazolinil) piperidina como agonistas del receptor orl1 | |
| CU23423B7 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea | |
| UY28578A1 (es) | Derivados de amida | |
| ECSP23076800A (es) | Derivados de pirazolopiridina y sus usos | |
| ES2616089T3 (es) | Composición cosmética | |
| ES2508591T3 (es) | Agente para suprimir la formación de células de la piel anormales causada por la exposición a la luz | |
| AR037496A1 (es) | Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables | |
| DOP2025000099A (es) | Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos | |
| BR9706891A (pt) | Composto, medicamento, composição farmacêutica e composição cosmética. | |
| GT199900083A (es) | Combinaciones terapeuticas para la fragilidad musculoesqueletica. | |
| AR046665A1 (es) | Formulaciones orales de desoxipeganina y sus usos | |
| AR033779A1 (es) | Compuestos utiles en la enfermedad de reflujo | |
| ES2173968T3 (es) | Compuesto oxidente heterociclico de tres ciclos fusinados. | |
| BR0114339A (pt) | Composições farmaceuticamente aceitáveis contendo epinastina e pseudoefedrina | |
| ECSP055673A (es) | Derivados de 4-(3,5-dicianofenoxi) pirazol para el uso como moduladores de transcriptasa reversa en el tratamiento del vih | |
| ES2242075T3 (es) | Composicion topica que contiene brucina y utilizacion para el tratamiento de la piel dañada de un mamifero. | |
| AR004402A1 (es) | Sulfonas ciclicas, procedimiento para prepararlas, preparaciones farmaceuticas que las contienen y empleo de las mismas para combatir enfermedades. | |
| DK0453337T3 (da) | Anvendelse af hexetidin eller derivater eller salte deraf til fremstilling af et farmaceutisk præparat til oftalmologisk anvendelse | |
| BRPI0410664A (pt) | derivados de benzopirano substituìdos com um derivado de tioxobenzoxazole, sais farmaceuticamente aceitáveis destes, suas preparações e composições farmacêuticas contendo os mesmos | |
| BR0106261A (pt) | Composições medicamentosas contendo alcalóides indólicos para o tratamento da aids | |
| AR056908A1 (es) | Los oligonucleotidos y sus usos | |
| GT198700077A (es) | Un procedimiento de preparacion de una formulacion farmaceutica que comprende 3'-azido-3'desoxitimidina. | |
| AR027032A1 (es) | Derivados de analogos de benzimidazol sustituidos de homopiperidinilo |